Aminothiazole inhibitors of HCV RNA polymerase.
Bioorganic & medicinal chemistry letters 2005 Jan 3; 15(1):115-9
Shipps G GW, Deng Y Y, Wang T T, Popovici-Muller J J, Curran P PJ, Rosner K KE, Cooper A AB, Girijavallabhan V V, Butkiewicz N N, Cable M M
NeoGenesis Pharmaceuticals Inc., Department of Chemistry, 840 Memorial Drive, Cambridge, MA 02139, USA. shipps@neogenesis.com
Aminothiazole-based inhibitors designed for HCV polymerase display low micromolar potencies in biochemical assays. These compounds show a stringent preference for a cyclohexyl hydrophobe at the 2-amino position. The composition of these compounds suggests that they may be interacting at a recently discovered allosteric site on the polymerase.

